Does asymmetric dimethylarginine inhibit nitric oxide synthase and impair blood-vessel relaxation?

Asymmetric dimethylarginine (ADMA) is an endogenous regulator of nitric-oxide signaling. The stated pathway—from NOS inhibition to reduced endothelial nitric oxide (NO) and diminished vessel relaxation—is strongly supported mechanistically and is consistent with human physiological findings.

Clinical and vascular evidence

• ADMA competitively inhibits nitric oxide synthase (NOS) by competing with L-arginine, reducing NO production.
• Since endothelial NOS-derived NO is a principal driver of endothelium-dependent vasodilation, lower NO availability predictably impairs vascular smooth-muscle relaxation.
• In people with hypercholesterolemia, higher plasma ADMA was inversely associated with NO-mediated forearm vasodilation. L-arginine infusion increased the L-arginine/ADMA ratio, improved vasodilation, and increased urinary nitrate excretion, consistent with restoration of NO activity.
• Experimental ADMA administration has reduced forearm blood flow and renal plasma flow. A small healthy-volunteer infusion study also found lower circulating cyclic guanosine monophosphate (cGMP), the key downstream intracellular signal through which NO promotes relaxation.
• Prospectively, participants in the highest versus lowest ADMA third had approximately 40% higher subsequent cardiovascular-disease risk. This establishes prognostic association, not that ADMA itself is necessarily the causal driver.

Mechanistic interpretation

• The biological sequence is coherent: ADMA → competitive NOS inhibition → reduced endothelial NO → reduced cGMP signaling in vascular smooth muscle → impaired endothelium-dependent relaxation.
• This mechanism can contribute to endothelial dysfunction, but ADMA is one influence among multiple vascular, metabolic, and inflammatory processes.

Clinical considerations

• Human infusion studies were small, and some effects occurred at ADMA concentrations above usual endogenous levels. The magnitude of vascular impairment attributable to typical circulating ADMA remains uncertain.
• In an older-adult controlled study, impaired flow-mediated dilation was not explained by increased ADMA expression or acute L-arginine availability alone.

Bottom line

• ADMA-mediated NOS inhibition can reduce endothelial NO bioavailability and impair vessel relaxation; the direction of effect is well established, while its independent clinical importance at routine ADMA levels is less certain.